Literature DB >> 3142279

In vivo bioassay of endothelium-derived relaxing factor.

H A Kontos1, E P Wei, J J Marshall.   

Abstract

We devised a technique for the in vivo assay of endothelium-derived relaxing factor (EDRF) from cerebral microvessels. We used anesthetized cats equipped with two cranial windows. One window (assay window) was subjected to muscarinic blockade with atropine to inhibit the direct effects of acetylcholine. EDRF production was induced in the donor window by superfusion with acetylcholine. The superfusate was then directed through the assay window with a delay of 6 s where it caused vasodilation equal to that seen in the donor window. The dilation was eliminated by lengthening the transit time from the donor to the assay window to greater than 2 min or by muscarinic blockade with atropine in the donor window but not by indomethacin in the donor window. It was also inhibited by hemoglobin and methylene blue or by selective damage to the endothelium of the vessels in the donor window with topical application of arachidonate or hydrogen peroxide. We conclude that the vasoactivity of the superfusate is due to EDRF released by acetylcholine from cerebral microvessels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142279     DOI: 10.1152/ajpheart.1988.255.5.H1259

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

1.  Therapeutic targeting of the axonal and microvascular change associated with repetitive mild traumatic brain injury.

Authors:  Takashi Miyauchi; Enoch P Wei; John T Povlishock
Journal:  J Neurotrauma       Date:  2013-08-27       Impact factor: 5.269

2.  Does nitric oxide mediate the increases in cerebral blood flow elicited by hypercapnia?

Authors:  C Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

3.  The combination of either tempol or FK506 with delayed hypothermia: implications for traumatically induced microvascular and axonal protection.

Authors:  Motoki Fujita; Yasutaka Oda; Enoch P Wei; John T Povlishock
Journal:  J Neurotrauma       Date:  2011-07       Impact factor: 5.269

Review 4.  Role of endothelial nitric oxide in cerebrovascular regulation.

Authors:  Dmitriy N Atochin; Paul L Huang
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

5.  Combinational therapy using hypothermia and the immunophilin ligand FK506 to target altered pial arteriolar reactivity, axonal damage, and blood-brain barrier dysfunction after traumatic brain injury in rat.

Authors:  Yasutaka Oda; Guoyi Gao; Enoch P Wei; John T Povlishock
Journal:  J Cereb Blood Flow Metab       Date:  2010-12-15       Impact factor: 6.200

6.  The adverse pial arteriolar and axonal consequences of traumatic brain injury complicated by hypoxia and their therapeutic modulation with hypothermia in rat.

Authors:  Guoyi Gao; Yasutaka Oda; Enoch P Wei; John T Povlishock
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

7.  Role of hydrogen peroxide and the impact of glutathione peroxidase-1 in regulation of cerebral vascular tone.

Authors:  Mary L Modrick; Sean P Didion; Cynthia M Lynch; Sanjana Dayal; Steven R Lentz; Frank M Faraci
Journal:  J Cereb Blood Flow Metab       Date:  2009-04-08       Impact factor: 6.200

8.  Cerebral blood flow and cerebrovascular reactivity after inhibition of nitric oxide synthesis in conscious goats.

Authors:  N Fernández; J L García; A L García-Villalón; L Monge; B Gómez; G Diéguez
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 9.  The role of oxidative stress and NADPH oxidase in cerebrovascular disease.

Authors:  Sophocles Chrissobolis; Frank M Faraci
Journal:  Trends Mol Med       Date:  2008-10-15       Impact factor: 11.951

10.  The long-term microvascular and behavioral consequences of experimental traumatic brain injury after hypothermic intervention.

Authors:  Enoch P Wei; Robert J Hamm; Anna I Baranova; John T Povlishock
Journal:  J Neurotrauma       Date:  2009-04       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.